

# Peter M Irving

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7647013/publications.pdf>

Version: 2024-02-01

217  
papers

11,363  
citations

26630

56  
h-index

33894

99  
g-index

229  
all docs

229  
docs citations

229  
times ranked

10322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gluten Causes Gastrointestinal Symptoms in Subjects Without Celiac Disease: A Double-Blind Randomized Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, 508-514.	0.4	606
2	Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1366-1373.	2.8	476
3	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	8.1	431
4	Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. <i>Journal of Nutrition</i> , 2012, 142, 1510-1518.	2.9	430
5	Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , 2011, 24, 487-495.	2.5	350
6	A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2017, 153, 936-947.	1.3	315
7	Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 874-882.	3.7	295
8	Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific $\gamma\delta$ T Cell Compartments. <i>Cell</i> , 2016, 167, 203-218.e17.	28.9	273
9	Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 8-14.	1.3	256
10	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	1.3	249
11	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	12.1	233
12	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	12.1	232
13	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1655-1668.e3.	4.4	214
14	Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. <i>Gastroenterology</i> , 2020, 158, 176-188.e7.	1.3	209
15	Mechanisms and efficacy of dietary FODMAP restriction in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 256-266.	17.8	198
16	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	21.4	165
17	Developing in vitro expanded CD45RA <sup>+</sup> regulatory T cells as an adoptive cell therapy for Crohn's disease. <i>Gut</i> , 2016, 65, 584-594.	12.1	163
18	The $\gamma\delta$ TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. <i>Nature Immunology</i> , 2018, 19, 1352-1365.	14.5	163

#	ARTICLE	IF	CITATIONS
19	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	12.1	153
20	Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1129-1136.	1.9	137
21	Thrombosis and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 617-628.	4.4	134
22	Association Between Response to Etrolizumab and Expression of Integrin $\alpha$ E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	1.3	133
23	Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13154.	3.0	132
24	Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 165-174.	3.7	131
25	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129
26	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2233-2240.e2.	4.4	109
27	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 714-724.	1.9	102
28	Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1420-1429.	1.3	100
29	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	8.1	100
30	Regulatory T-cell therapy in Crohn's disease: challenges and advances. <i>Gut</i> , 2020, 69, 942-952.	12.1	99
31	Mechanism of allopurinol induced TPMT inhibition. <i>Biochemical Pharmacology</i> , 2013, 86, 539-547.	4.4	96
32	Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. <i>Lancet</i> , 2022, 399, 2200-2211.	13.7	94
33	Formation of Platelet-leukocyte Aggregates in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 361-372.	1.9	92
34	Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 905-912.	1.3	92
35	Patient optimization for surgery relating to Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 707-719.	17.8	92
36	Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1301-1307.	1.9	91

#	ARTICLE	IF	CITATIONS
37	Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 385-391.e1.	4.4	90
38	Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 119-130.	3.7	88
39	Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 910-923.	3.7	87
40	Infections and IBD. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2008, 5, 18-27.	1.7	86
41	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158.	1.3	85
42	The challenges of control groups, placebos and blinding in clinical trials of dietary interventions. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 203-212.	1.0	83
43	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	17.8	82
44	Cutting Edge: Regulator of G Protein Signaling-1 Selectively Regulates Gut T Cell Trafficking and Colitic Potential. <i>Journal of Immunology</i> , 2011, 187, 2067-2071.	0.8	78
45	Review article: appropriate use of corticosteroids in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 313-329.	3.7	77
46	Small bowel MR enterography: problem solving in Crohn's disease. <i>Insights Into Imaging</i> , 2012, 3, 251-263.	3.4	75
47	Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1385-1393.	1.3	74
48	Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , 2015, 28, 687-696.	2.5	73
49	Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2020, 120, 535-547.	0.8	73
50	Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation. <i>Gastroenterology</i> , 2015, 149, 456-467.e15.	1.3	71
51	Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 249-253.	1.6	70
52	Fructan content of commonly consumed wheat, rye and gluten-free breads. <i>International Journal of Food Sciences and Nutrition</i> , 2011, 62, 498-503.	2.8	67
53	Optimization of conventional therapy in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 646-656.	17.8	66
54	Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1097-1108.	3.7	65

#	ARTICLE	IF	CITATIONS
55	Improving quality of care in inflammatory bowel disease: What changes can be made today?. Journal of Crohn's and Colitis, 2014, 8, 919-926.	1.3	65
56	Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World Journal of Gastroenterology, 2008, 14, 5020.	3.3	63
57	Anti-infliximab antibodies in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2012, 24, 1078-1085.	1.6	59
58	Benefits of breath hydrogen testing after lactulose administration in analysing carbohydrate malabsorption. European Journal of Gastroenterology and Hepatology, 2010, 22, 318-326.	1.6	58
59	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs, 2020, 80, 99-113.	10.9	58
60	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	8.1	57
61	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology and Therapeutics, 2014, 40, 1313-1323.	3.7	55
62	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Alimentary Pharmacology and Therapeutics, 2017, 46, 150-161.	3.7	53
63	A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterology, 2018, 9, 10-15.	1.8	53
64	The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. International Journal of Clinical Practice, 2013, 67, 161-169.	1.7	52
65	Î²-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. American Journal of Gastroenterology, 2020, 115, 906-915.	0.4	50
66	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
67	The Glasgow Blatchford scoring system enables accurate risk stratification of patients with upper gastrointestinal haemorrhage. International Journal of Clinical Practice, 2010, 64, 868-874.	1.7	47
68	The Appropriateness of Concomitant Immunomodulators With Anti-“Tumor Necrosis Factor Agents for Crohn’s Disease: One Size Does Not Fit All. Clinical Gastroenterology and Hepatology, 2010, 8, 655-659.	4.4	46
69	Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infectious Diseases and Therapy, 2018, 7, 71-86.	4.0	45
70	Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics. Clinical Nutrition, 2021, 40, 1861-1870.	5.0	44
71	Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. Gastroenterology, 2022, 162, 1512-1524.	1.3	44
72	Î±Î²7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 11, jjw189.	1.3	43

#	ARTICLE	IF	CITATIONS
73	Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2839-2847.	1.9	42
74	Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000573.	2.7	42
75	Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. <i>Frontline Gastroenterology</i> , 2017, 8, 196-202.	1.8	41
76	Correction of Defective T-Regulatory Cells From Patients With Crohn's Disease by Ex Vivo Ligation of Retinoic Acid Receptor- $\alpha$ . <i>Gastroenterology</i> , 2019, 156, 1775-1787.	1.3	40
77	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	1.3	39
78	Toxicity and response to thiopurines in patients with inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 891-900.	3.0	37
79	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2020, 11, 343-350.	1.8	37
80	Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1018-1035.	2.3	37
81	Poster presentations at medical conferences: an effective way of disseminating research?. <i>Clinical Medicine</i> , 2011, 11, 138-141.	1.9	36
82	Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1302-1309.	4.4	36
83	Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. <i>Frontline Gastroenterology</i> , 2016, 7, 122-128.	1.8	36
84	Hidradenitis Suppurativa. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 762-771.	1.3	35
85	Platelet-leucocyte aggregates form in the mesenteric vasculature in patients with ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 283-289.	1.6	33
86	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	8.1	33
87	Use of azathioprine in IBD: modern aspects of an old drug. <i>Gut</i> , 2014, 63, 1695-1699.	12.1	32
88	Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14241.	3.0	31
89	Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. <i>United European Gastroenterology Journal</i> , 2017, 5, 563-570.	3.8	30
90	Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 937-944.	1.9	29

#	ARTICLE	IF	CITATIONS
91	Tofacitinib in Acute Severe Ulcerative Colitis—A Real-World Tertiary Center Experience. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e147-e149.	1.9	28
92	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	12.1	28
93	Recent advances in monoclonal antibody therapy in IBD: practical issues. <i>Frontline Gastroenterology</i> , 2019, 10, 409-416.	1.8	27
94	Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study. <i>Evidence-Based Mental Health</i> , 2021, 24, 102-109.	4.5	26
95	Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. <i>RMD Open</i> , 2020, 6, e001392.	3.8	26
96	Biologic therapies for Crohn's disease: optimising the old and maximising the new. <i>F1000Research</i> , 2019, 8, 1210.	1.6	25
97	Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in) <i>Tj ETQq1 1 0.7874314 rg24 /Over</i>	1.3	24
98	Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients. <i>Scientific Reports</i> , 2019, 9, 14042.	3.3	24
99	Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 735-743.	1.3	24
100	Percutaneous endoscopic gastrostomy with a jejunal port for severe hyperemesis gravidarum. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 937-939.	1.6	23
101	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	8.1	23
102	Nutrient, Fibre, and FODMAP Intakes and Food-related Quality of Life in Patients with Inflammatory Bowel Disease, and Their Relationship with Gastrointestinal Symptoms of Differing Aetiologies. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2041-2053.	1.3	23
103	Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, E39-E40.	1.9	22
104	Colitis Caused by Clostridium difficile Infection: Report of a Case. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1074-1077.	1.3	21
105	Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 685-689.	1.8	21
106	Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1418-1424.	1.9	21
107	Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1555-1565.	1.9	21
108	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	3.8	20

#	ARTICLE	IF	CITATIONS
109	IBD2020 global forum: results of an international patient survey on quality of care. <i>Intestinal Research</i> , 2018, 16, 537-545.	2.6	20
110	Drug Interactions in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 207-219.	0.4	19
111	Hair Loss in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1753-1763.	1.9	18
112	Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 908-916.e13.	4.4	18
113	Gastrointestinal: Rapunzel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 2361-2361.	2.8	17
114	Optimising use of thiopurines in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 877-888.	3.0	17
115	Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 292-302.	3.7	17
116	An audit of admissions of patients with epilepsy to a district general hospital. <i>Seizure: the Journal of the British Epilepsy Association</i> , 1999, 8, 166-169.	2.0	15
117	Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1271-1279.	3.1	15
118	Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?. <i>Frontiers in Medicine</i> , 2019, 6, 279.	2.6	15
119	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 839-841.e2.	4.4	15
120	Acute mesenteric infarction: an important cause of abdominal pain in ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1429-1432.	1.6	14
121	The challenges of control groups, placebos and blinding in clinical trials of dietary interventions. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 628-628.	1.0	14
122	The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre. <i>GastroHep</i> , 2020, 2, 318-326.	0.6	14
123	Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. <i>Frontline Gastroenterology</i> , 2020, 11, 188-193.	1.8	14
124	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	1.9	14
125	Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1338-1347.	1.9	14
126	A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 646-663.	3.7	14



#	ARTICLE	IF	CITATIONS
127	Management of distal ulcerative colitis: frequently asked questions analysis. <i>Internal Medicine Journal</i> , 2008, 38, 114-119.	0.8	13
128	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e143-e145.	1.9	13
129	Golimumab in the treatment of ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481882126.	3.2	13
130	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1769-1776.	1.3	13
131	Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2021, 70, 1044-1052.	12.1	13
132	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. <i>Annals of Gastroenterology</i> , 2020, 33, 170-177.	0.6	13
133	979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data. <i>Gastroenterology</i> , 2013, 144, S-179.	1.3	12
134	Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. <i>Frontline Gastroenterology</i> , 2018, 9, 221-231.	1.8	12
135	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1051-1058.	1.5	12
136	Optimizing conventional therapies for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2009, 11, 496-503.	2.5	11
137	COVID-19 and IBD drugs: should we change anything at the moment?. <i>Gut</i> , 2021, 70, 632-634.	12.1	11
138	Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2294-2300.	1.9	10
139	Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e125-e126.	1.9	10
140	Vedolizumab-Associated Drug-Induced Liver Injury: A Case Series. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e32-e34.	1.9	10
141	Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. <i>Pharmacogenomics</i> , 2009, 10, 1091-1099.	1.3	9
142	Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1653-1661.	1.3	9
143	Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. <i>Frontline Gastroenterology</i> , 2022, 13, 517-523.	1.8	9
144	1133 The Low FODMAP Diet Reduces Symptoms in Irritable Bowel Syndrome Compared With Placebo Diet and the Microbiota Alterations May Be Prevented by Probiotic Co-Administration: A 2x2 Factorial Randomized Controlled Trial. <i>Gastroenterology</i> , 2016, 150, S230.	1.3	8

#	ARTICLE	IF	CITATIONS
145	Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 57-66.	2.3	8
146	Leucocytapheresis for ulcerative colitis. <i>Digestive and Liver Disease</i> , 2004, 36, 799-802.	0.9	7
147	An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 678-688.	3.7	7
148	Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. <i>Circulation: Heart Failure</i> , 2021, 14, .	3.9	7
149	Depression, anxiety, and stress among inflammatory bowel disease patients during COVID-19: A UK cohort study. <i>JGH Open</i> , 2022, 6, 76-84.	1.6	7
150	Review article: randomised controlled trials in inflammatory bowel disease—common challenges and potential solutions. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 658-669.	3.7	7
151	Biologics for inflammatory bowel diseases in the Asia-Pacific: Can we afford to use them, can we afford not to?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1160-1162.	2.8	6
152	Quality, clinical influence and tolerance of computed tomography enteroclysis in patients with suspected small bowel disease. <i>Internal Medicine Journal</i> , 2009, 39, 733-743.	0.8	6
153	New role for azathioprine in case of switching anti-TNFs in IBD. <i>Gut</i> , 2020, 69, 1165-1167.	12.1	6
154	Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. <i>Digestive Diseases</i> , 2018, 36, 33-39.	1.9	6
155	What changes in inflammatory bowel disease management can be implemented today?. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S260-S267.	1.3	5
156	Inflammatory bowel disease in pregnancy: management strategy based on best evidence and European guidelines. <i>British Journal of General Practice</i> , 2014, 64, 593-594.	1.4	5
157	ECCO IBD Curriculum. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1039-1043.	1.3	5
158	A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK. <i>Medicine (United States)</i> , 2019, 98, e14681.	1.0	5
159	Positioning biologics and new therapies in the management of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 296-301.	2.3	5
160	A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2054-2065.	1.3	5
161	Alopecia areata: A possible extraintestinal manifestation of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e503.	1.3	4
162	Semiquantitative assessment of breath hydrogen testing. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1450-1456.	2.8	4

#	ARTICLE	IF	CITATIONS
163	Are We Using and Monitoring Thiopurines and Biologics Optimally?. <i>Digestive Diseases</i> , 2014, 32, 410-418.	1.9	4
164	Distinct management issues with Crohn's disease of the small intestine. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 92-97.	2.3	4
165	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1829-1831.	4.4	4
166	Can we get more from our current treatments?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 451-463.	2.4	3
167	343 Azathioprine Decreases the Risk of Adalimumab Primary Non-Response and Secondary Loss of Response but Only if Adequately Dosed. <i>Gastroenterology</i> , 2014, 146, S-79.	1.3	3
168	How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?. <i>World Journal of Gastroenterology</i> , 2015, 21, 11331.	3.3	3
169	The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 975-977.	3.1	3
170	De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. <i>GastroHep</i> , 2019, 1, 108-117.	0.6	3
171	Common infections, mental health problems and healthcare use in people with inflammatory bowel disease: a cohort study protocol. <i>Evidence-Based Mental Health</i> , 2021, 24, 82-87.	4.5	3
172	Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. <i>BioDrugs</i> , 2021, 35, 187-199.	4.6	3
173	The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study. <i>JMIR Research Protocols</i> , 2018, 7, e11218.	1.0	3
174	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. <i>Gut</i> , 2022, 71, 661-664.	12.1	3
175	Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 822-834.	1.3	3
176	Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel. <i>Journal of Crohn's and Colitis</i> , 0, , .	1.3	3
177	Positioning intestinal ultrasound in a UK tertiary centre: significant estimated clinical role and cost savings. <i>Frontline Gastroenterology</i> , 2023, 14, 52-58.	1.8	3
178	Diverticular disease of the colon. <i>Lancet, The</i> , 2004, 363, 1397.	18.7	2
179	CMV co-Infection" Does it Matter?. , 0, , 159-163.		2
180	Platelet-leucocyte aggregation in IBD. <i>American Journal of Hematology</i> , 2007, 82, 686-686.	4.1	2

#	ARTICLE	IF	CITATIONS
181	The future developments in inflammatory bowel disease care: Table 1. <i>Frontline Gastroenterology</i> , 2012, 3, i42-i46.	1.8	2
182	Utilisation of anti-TNF levels in a UK tertiary IBD centre. <i>Frontline Gastroenterology</i> , 2017, 8, 189-195.	1.8	2
183	Faecal microbiota transplantation for refractory <i>Clostridium difficile</i> infection. <i>BMJ Case Reports</i> , 2019, 12, e231027.	0.5	2
184	Editorial: establishing a joint approach to a common problem for gastroenterologists. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 306-307.	3.7	2
185	Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 341-342.	3.7	2
186	Successful faecal microbiota transplant for recurrent <i>Clostridium difficile</i> infection delivered by colonoscopy through a diverted ileostomy in a patient with severe perianal Crohn's disease. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-222958.	0.5	2
187	Intestinal Infections: Mimics and Precipitants of Relapse. , 0, , 217-221.		1
188	Infliximab: Getting the most for your money. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1559-1561.	2.8	1
189	Recent advances in the management of inflammatory bowel disease. <i>Clinical Medicine</i> , 2009, 9, 605-608.	1.9	1
190	Biosimilars: what's around the corner?. <i>Frontline Gastroenterology</i> , 2015, 6, 262-263.	1.8	1
191	Letter: immune checkpoint inhibitor-induced colitis "shouldn't we be checking more often?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 472-473.	3.7	1
192	Vedolizumab Dose Escalation: In for a Penny, in for a Pound?. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1772-1774.	2.3	1
193	S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn's Disease: IBDQ in the SEAVUE Study. <i>American Journal of Gastroenterology</i> , 2021, 116, S355-S357.	0.4	1
194	Pulmonary Manifestations: Rare But Real. , 0, , 213-216.		0
195	Leukocytapheresis: Filtering Out the Facts. , 0, , 105-107.		0
196	Thromboembolic Disease: An Under-Recognized Complication?. , 0, , 209-212.		0
197	Leukocytapheresis in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2006, 101, 203-204.	0.4	0
198	Steroids in villous atrophy: opening a can of worms?. <i>Frontline Gastroenterology</i> , 2012, 3, 199-200.	1.8	0

#	ARTICLE	IF	CITATIONS
199	Oesophageal Crohn's disease: A novel approach to managing iatrogenic perforation of an oesophageal Crohn's stricture. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 332-333.	1.3	0
200	Current management options and recent advances in IBD. <i>The Prescriber</i> , 2014, 25, 18-22.	0.3	0
201	Characterisation of the lymphoid stress surveillance response in human intestine. <i>Lancet, The</i> , 2016, 387, S33.	13.7	0
202	Biologic Therapy of Ulcerative Colitis: Golimumab. , 2017, , 441-448.		0
203	Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 465-465.	3.7	0
204	Authors' Reply to: Type C Mucosa in Pouch Surveillance: Make-do and Mend Rather Than Start From Scratch?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1181-1181.	1.3	0
205	Striking the balance with intravenous iron: too much or never enough?. <i>Frontline Gastroenterology</i> , 2021, 12, 361-362.	1.8	0
206	P334...Measuring oesophageal transit with multichannel intraluminal impedance; an alternative to barium swallow. , 2021, , .		0
207	P339...Novel approach to assess retention in dysphagia patients with post anti-reflux surgery. , 2021, , .		0
208	P338...Assessing oesophageal clearance in post peroral endoscopic myotomy: introducing a novel technique. , 2021, , .		0
209	P340...Oesophageal transit during fasting and non-fasting period in patients with dysphagia. , 2021, , .		0
210	P333...Baseline mucosal impedance predicting the outcome of bravo pH study. , 2021, , .		0
211	P337...Evaluating modern reflux monitoring methods with respect to medical therapy. , 2021, , .		0
212	P336...Multichannel intraluminal impedance transit in patients with obstructive disorders. , 2021, , .		0
213	P335...Multichannel intraluminal impedance transit testing in patients with functional dysphagia. , 2021, , .		0
214	Colonoscopy completion rates: Technologies have evolved. <i>BMJ: British Medical Journal</i> , 2004, 329, 1287.3.	2.3	0
215	Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGE Group. <i>Gastroenterology and Hepatology</i> , 2008, 4, 713-20.	0.1	0
216	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	2.3	0

#	ARTICLE	IF	CITATIONS
217	Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn's Disease. GastroHep, 2022, 2022, 1-12.	0.6	0